What is Zacks Research’s Forecast for BHC Q3 Earnings?

Bausch Health Companies Inc. (NYSE:BHC) – Equities research analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for Bausch Health Companies in a research report issued to clients and investors on Tuesday, December 17th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.15 per share for the quarter, up from their prior forecast of $1.12. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.25 EPS.

BHC has been the subject of several other reports. Royal Bank of Canada boosted their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Stock Performance

NYSE BHC opened at $7.47 on Friday. The stock has a market capitalization of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46. The stock has a fifty day moving average of $8.33 and a 200-day moving average of $7.28.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the firm earned $1.03 earnings per share. Bausch Health Companies’s revenue was up 12.2% compared to the same quarter last year.

Institutional Investors Weigh In On Bausch Health Companies

Several large investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $35,000. MQS Management LLC acquired a new stake in shares of Bausch Health Companies during the second quarter worth about $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies during the 2nd quarter valued at about $75,000. Bfsg LLC grew its position in shares of Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management bought a new stake in Bausch Health Companies during the 2nd quarter worth approximately $87,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.